Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Objective: We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity. Methods: In this cross-sectional multicenter study (a subset of the prospective Swedish BioFINDER study), we included 4 groups, representing the different stages of predementia AD: (1) cognitively healthy elderly with normal CSF β-amyloid 42 (Aβ42), (2) cognitively healthy elderly with abnormal CSF Aβ42, (3) patients with subjective cognitive decline and abnormal CSF Aβ42, (4) patients with mild cognitive decline and abnormal CSF Aβ42 (N total 352). Spectroscopic markers measured in the posterior cingulate/precuneus were considered alongside known disease biomarkers: CSF Aβ42, phosphorylated tau, total tau, [18 F]-flutemetamol PET, f-MRI, and the genetic risk factor APOE. Results: Amyloid-positive cognitively healthy participants showed a significant increase in mI/creatine and mI/NAA levels compared to amyloid-negative healthy elderly (p <0.05). In amyloid-positive healthy elderly, mI/creatine and mI/NAA correlated with cortical retention of [18 F] flutemetamol tracer (0.44, p 0.02 and 0.51, p 0.01, respectively). Healthy elderly APOE ϵ4 carriers with normal CSF Aβ42 levels had significantly higher mI/creatine levels (p <0.001) than ϵ4 noncarriers. Finally, elevated mI/creatine was associated with decreased functional connectivity within the default mode network (r pearson-0.16, p 0.02), independently of amyloid pathology. Conclusions: mI levels are elevated already at asymptomatic stages of AD. Moreover, mI/creatine concentrations were increased in healthy APOE ϵ4 carriers with normal CSF Aβ42 levels, suggesting that mI levels may reveal regional brain consequences of APOE ϵ4 before detectable amyloid pathology.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Karolinska Institute
  • University College London
  • Skåne University Hospital
  • Sahlgrenska University Hospital
  • Göteborgs universitet
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurologi
Originalspråkengelska
Sidor (från-till)1754-1761
Antal sidor8
TidskriftNeurology
Volym86
Utgåva nummer19
StatusPublished - 2016 maj 10
PublikationskategoriForskning
Peer review utfördJa